Published by mark itwired
Posted on September 20, 2021
According to latest research by FMI, the global gene editing tools market is estimated to have accounted for more than US$ 258 Mn in terms of value in 2018. The report on the gene editing tools market further projects that the gene editing tools market is likely to grow at a CAGR of over 18% during the period 2019-2029.
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) segment is a leading segment in terms of revenue by product type in the gene editing tools market, and accounted for an approximate revenue share of 75% in 2018. CRISPR/Cas9 gene editing tools are most widely used by scientists to create transgenic animals that include zebrafish, pigs, mice, rats, and primates. Among all the distribution channels in the gene editing tools market, the academic and research institutes segment is expected to be most prominent segment, followed by biotech and pharmaceutical companies.
The rising prevalence of cancer and other genetic disorders, such as sickle cell disease, heart disease, diabetes, Alzheimer’s disease, obesity, and others, is among the key factors impacting the growth of gene editing tools market. Cancer is registered to be the second most prominent cause of death worldwide. According to the World Health Organization (WHO), the number of deaths due to cancer worldwide in 2015 was 8.8 million. However, cancer alone was responsible for an estimated 9.6 million deaths globally in 2018.
Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-9544
Worldwide, approximately about 1 in 6 deaths occur owing to cancer. An analysis states that approximately 70% of deaths due to cancer occur in low- and middle-income countries. Thus, gene editing is most preferred for the management of rare genetic disorders, which is driving the demand for gene editing, thus generating a favourable revenue opportunity for gene editing tools.
The growing prevalence and incidence of rare genetic disorders, majorly Sickle Cell Disease (SKD), cancer, and Alzheimer’s disease, is leading to the high demand for genome editing, and is one of the leading factors that is contributing significantly to the growth of the gene editing tools market. Moreover, gene editing tools, such as CRISPR, TALENs, and ZFNs, find precise applications in the treatment of cancer. Owing to the high efficiency and accuracy of the CRISPR-Cas9 gene editing technique, it has emerged as a potential tool for cancer therapy. Among its various applications, CRISPR-Cas9 has a high clinical potential to detect novel target genes for cancer therapy.
Introduction of technologically advanced gene editing tools is expected to boost the growth of gene editing tools market. Recent advancements in CRISPR gene editing tools and their ease of use have generated significant interest in the biomedical community. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene editing has high potential to cater to the therapeutic landscape of induced disorders, owing to the presence of key players in the industry such as Intellia, CRISPR Therapeutics, and Editas. CRISPR gene editing tools offer precise gene-targeted treatments for β-thalassemia and SKD. Among gene editing tools, there are potential applications for CRISPR in the gene editing tools market in human therapeutics as well as veterinary therapeutics.
North America, followed by Europe, is a prominent region in the global gene editing tools market. North America accounts for a revenue share of about 25.0% in 2018 in gene editing tools market. Europe accounting for the second-largest revenue share, and is followed by South Asia in the gene editing tools market. India, China, and Japan are among the emerging markets in the gene editing tools market. Japan is among the fastest-growing emerging markets in the global gene editing tools market, and is projected to grow at a CAGR of more than 6% during the forecast period of 2019-2029.
The gene editing tools market report tracks some of the key companies operating in gene editing tools market, such as Thermo Fisher Scientific Inc., ERS Genomics, CRISPR THERAPEUTICS, Merck KGaA, Editas Medicine, Takara Bio USA, New England Biolabs, Intellia Therapeutics, Inc., and GenScript Biotech Corporation. Majority of the key regional players in the gene editing tools market are focused on increasing their product reach and connectivity with the help of domestic distributors of gene editing tools. Moreover, the manufacturers of gene editing tools are focused to strengthening their businesses in high-growth markets, such as India, Japan, China, and Argentina, by expanding their sales and distribution channels across these countries.
The post Gene Editing Tools Market Outlook and Opportunities in Grooming Regions 2029 first appeared on Market Research Blog.
According to latest research by FMI, the global gene editing tools market is estimated to have accounted for more than US$ 258 Mn in terms of value in 2018. The report on the gene editing tools market further projects that the gene editing tools market is likely to grow at a CAGR of over 18% during the period 2019-2029.
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) segment is a leading segment in terms of revenue by product type in the gene editing tools market, and accounted for an approximate revenue share of 75% in 2018. CRISPR/Cas9 gene editing tools are most widely used by scientists to create transgenic animals that include zebrafish, pigs, mice, rats, and primates. Among all the distribution channels in the gene editing tools market, the academic and research institutes segment is expected to be most prominent segment, followed by biotech and pharmaceutical companies.
The rising prevalence of cancer and other genetic disorders, such as sickle cell disease, heart disease, diabetes, Alzheimer’s disease, obesity, and others, is among the key factors impacting the growth of gene editing tools market. Cancer is registered to be the second most prominent cause of death worldwide. According to the World Health Organization (WHO), the number of deaths due to cancer worldwide in 2015 was 8.8 million. However, cancer alone was responsible for an estimated 9.6 million deaths globally in 2018.
Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-9544
Worldwide, approximately about 1 in 6 deaths occur owing to cancer. An analysis states that approximately 70% of deaths due to cancer occur in low- and middle-income countries. Thus, gene editing is most preferred for the management of rare genetic disorders, which is driving the demand for gene editing, thus generating a favourable revenue opportunity for gene editing tools.
The growing prevalence and incidence of rare genetic disorders, majorly Sickle Cell Disease (SKD), cancer, and Alzheimer’s disease, is leading to the high demand for genome editing, and is one of the leading factors that is contributing significantly to the growth of the gene editing tools market. Moreover, gene editing tools, such as CRISPR, TALENs, and ZFNs, find precise applications in the treatment of cancer. Owing to the high efficiency and accuracy of the CRISPR-Cas9 gene editing technique, it has emerged as a potential tool for cancer therapy. Among its various applications, CRISPR-Cas9 has a high clinical potential to detect novel target genes for cancer therapy.
Introduction of technologically advanced gene editing tools is expected to boost the growth of gene editing tools market. Recent advancements in CRISPR gene editing tools and their ease of use have generated significant interest in the biomedical community. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene editing has high potential to cater to the therapeutic landscape of induced disorders, owing to the presence of key players in the industry such as Intellia, CRISPR Therapeutics, and Editas. CRISPR gene editing tools offer precise gene-targeted treatments for β-thalassemia and SKD. Among gene editing tools, there are potential applications for CRISPR in the gene editing tools market in human therapeutics as well as veterinary therapeutics.
North America, followed by Europe, is a prominent region in the global gene editing tools market. North America accounts for a revenue share of about 25.0% in 2018 in gene editing tools market. Europe accounting for the second-largest revenue share, and is followed by South Asia in the gene editing tools market. India, China, and Japan are among the emerging markets in the gene editing tools market. Japan is among the fastest-growing emerging markets in the global gene editing tools market, and is projected to grow at a CAGR of more than 6% during the forecast period of 2019-2029.
The gene editing tools market report tracks some of the key companies operating in gene editing tools market, such as Thermo Fisher Scientific Inc., ERS Genomics, CRISPR THERAPEUTICS, Merck KGaA, Editas Medicine, Takara Bio USA, New England Biolabs, Intellia Therapeutics, Inc., and GenScript Biotech Corporation. Majority of the key regional players in the gene editing tools market are focused on increasing their product reach and connectivity with the help of domestic distributors of gene editing tools. Moreover, the manufacturers of gene editing tools are focused to strengthening their businesses in high-growth markets, such as India, Japan, China, and Argentina, by expanding their sales and distribution channels across these countries.
The post Gene Editing Tools Market Outlook and Opportunities in Grooming Regions 2029 first appeared on Market Research Blog.
Explore more articles in the Research Reports category
